The Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results From the Randomized, Registrational, Phase 2 ChonDRAgon Study 21st Annual[...]

Inhibrx Biosciences Inc. published this content on November 14, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 14, 2025 at 15:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]